Product Description
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boston Children's Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Small Cell Lung Cancer|Breast Cancer|Non-Small-Cell Lung Cancer
Phase 1: Vascular Malformations
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CDR0000065585 | P3 |
Completed |
Breast Cancer |
2004-12-01 |
|
BR12 | P3 |
Completed |
Small Cell Lung Cancer |
2001-02-13 |
|
03-04-052R | P1 |
Completed |
Vascular Malformations |
None |
|
CDR0000065284 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
None |